C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics

In an encouraging sign for drug/diagnostic co-development, the independently funded C-Path Institute is now engaging more than 20 pharma and diagnostics companies with interests in non-small-cell lung cancer treatment using EGF receptor-targeted drugs and diagnostics. This proposed initiative could forge a template for future FDA reviews of drugs and companion diagnostics.